• Fulfilling the Promise of Personalized Medicine. Caris Life Sciences was founded because of an idea — that personalized and precise information can improve healthcare for everyone. This idea drives everything we do at Caris Life Sciences. Caris combines the rigor of an academic medical institution with the innovative spirit of a technology company. We believe that innovative, high-quality testing and information can lead to more effective treatment selection and ultimately to better outcomes for patients with cancer and other complex diseases. 

  • NanoString Technologies is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in( vitro diagnostics applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis.

  • Guardant Health is a pioneer in non-invasive cancer diagnostics and the first company to commercialize a comprehensive genomic liquid biopsy. Guardant Health proprietary digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. Guardant Health combined decades of scientific research, advances in laboratory technology, and its breakthrough innovation in liquid biopsy to create a test that has already handled tens of thousands of samples.

  • GeneKor is multinational molecular diagnostics company founded in 2007 and operates molecular biology laboratories with state of the art equipment suitable to provide the highest quality of Molecular Services . They provide a diversification of services focused on improving patient care utilizing the latest technologies of prognostic, predictive, and personalized medicine. The clinical expertise of GeneKor focuses on: Response to Targeted Therapy Pharmacogenetics Determination of Hereditary Cancer Diagnosis of NonOHereditary Cancer New Unique Technological Platforms Diagnosis of Genetic Diseases Diagnosis of Pathogenic Microorganisms at the Molecular Level.

  • MDxHealth is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer.  The increased adoption of our ConfirmMDx® for Prostate Cancer testing solution within the U.S. urology community has established MDxHealth as a market leader in the important and growing field of cancer epigenetics.